SUMMARY To investigate the role of brain catecholamines in the development of spontaneous hypertension, rats were treated with different doses of the neurotoxins 6-hydroxydopamine (6-OHDA) or -N-ethyl-2-bromobenzylamine hydrochloride). Intracerebroventricular (i.c.v.) 6-OHDA attenuated the development of hypertension in spontaneously hypertensive rats (SHR) and also lowered the systolic blood pressure (BP) in Wistar-Kyoto (WKY) and stroke-prone spontaneously hypertensive rats (SHRSP). Norepinephrine was markedly and dose-dependently depleted in brain areas of all three substrains. Dopamine was affected also, although to a lesser extent. Pretreatment with the norepinephrine-uptake inhibitor desmethylimipramine (DMI) did not influence the effect of 6-OHDA on the development of hypertension in SHR. DMI largely antagonized the 6-OHDA-induced depletion of brain norepinephrine, while dopamine depletion was not affected. Specific depletion of brain norepinephrine by treatment with DSP-4 did not alter the rise in BP in SHR. These results suggest that the effect of 6-OHDA on the development of hypertension in SHR may not be mediated through destruction of brain norepinephrine neurons, but that interruption of brain dopaminergic mechanisms is a possibility in this respect. (Hypertension 6: 899-905, 1984) KEY WORDS • 6-hydroxydopamine • DSP-4 • catecholamines • desmethylimipramine spontaneously hypertensive rat • Wistar-Kyoto rat • stroke-prone spontaneously hypertensive rat I T is now well established 1 " 3 that central catecholaminergic pathways are involved in the regulation of blood pressure (BP). Administration of norepinephrine, dopamine, and epinephrine to the nucleus tractus solitarii causes a decrease in BP and heart rate. We undertook the present experiments to further analyze the effect of i.c.v. 6-OHDA on the development of spontaneous hypertension. To separate the roles of dopamine and norepinephrine, we used 6-OHDA in combination with the norepinephrine uptake inhibitor desmethylimipramine (DMI), which selectively affects dopamine systems, 18 while we used the norepinephrine neurotoxin 1920 to affect only norepinephrine neurons. The results suggest a possible role of brain dopamine in the development of hypertension in the SHR.
I
T is now well established 1 " 3 that central catecholaminergic pathways are involved in the regulation of blood pressure (BP). Administration of norepinephrine, dopamine, and epinephrine to the nucleus tractus solitarii causes a decrease in BP and heart rate. 4 Age-dependent changes in the level and turnover of norepinephrine, 5 " 7 dopamine, 89 and epinephrine' 011 have been described in the brain of spontaneously hypertensive rats (SHR). It is as yet unclear, however, which of the catecholaminergic systems contributes most to the rise in BP in the SHR model of hypertension. Workers have shown that intracerebroventricular (i.c.v.) administration of 6-hydroxydopamine (6-OHDA), a neurotoxin selective for catecholaminergic neurons, 12 -13 to prehypertensive young SHR attenuates the development of hypertension in these animals. 14 This treatment causes marked depletion of norepinephrine, 15 l6 although dopamine 16 -" and, as shown recently, epinephrine 17 are affected as well.
We undertook the present experiments to further analyze the effect of i.c.v. 6-OHDA on the development of spontaneous hypertension. To separate the roles of dopamine and norepinephrine, we used 6-OHDA in combination with the norepinephrine uptake inhibitor desmethylimipramine (DMI), which selectively affects dopamine systems, 18 while we used the norepinephrine neurotoxin DSP-4 (N-[2 chloroethyl]-N-ethyl-2-bromobenzylamine hydrochloride) 1920 to affect only norepinephrine neurons. The results suggest a possible role of brain dopamine in the development of hypertension in the SHR.
Materials and Methods
We used male Wistar-Kyoto (WKY) normotensive control rats, SHR, and rats of the stroke-prone SHR substrain (SHRSP). 21 All rats were derived from breeding stocks at our institute (SHR-Cpb and WKY-Cpb 22 from TNO, Zeist, The Netherlands, were used for breeding of SHR and WKY). The animals were weaned at 4 weeks and kept in our laboratory under a constant light-dark regime with free access to standard pellet food and tap water.
To permit intracerebroventricular (i.c.v.) injections, the animals were operated on at the age of 4 weeks under Hypnorm anesthesia (fiuanison 10 mg and fentanyl 0.2 mg per ml, Duphar, Amsterdam, Theethylene cannulas were placed bilaterally in the lateral cerebral ventricles. After a recovery period of 5 to 7 days, the rats were injected consciously either with 6-OHDA, 50 or 200 ^ig dissolved as a base per 10 /u.1 0.9% saline with ascorbic acid (0.2 mg/ml), or injected with the vehicle only. Solutions were prepared freshly before the injections and were kept on ice. The first 10 /xl injection was given through the right ventricular cannula, and 48 hours later the second injection was administered through the left ventricular cannula. Again, 48 hours later, the third dose was given as two bilateral 5 /xl injections. Thus, rats injected i.c.v. with 6-OHDA received a total dose of 150 or 600 /Ltg of the base. After the third injection, the rats were allowed to recover for 3 days, and then they underwent training procedures to enable indirect BP measurement.
In case of pretreatment with DMI, 30 minutes before every i.c.v. injection the rats received an intraperitoneal (i.p.) injection of either DMI (25 mg/kg in distilled water, 1 ml/kg) 18 or the same volume of vehicle. Thus, in the DMI experiment, four animal groups were used: the control group received i.p. vehicle and i.c.v. vehicle, the DMI group received i.p. DMI and i.c.v. vehicle, the 6-OHDA group received i.p. vehicle and i.c.v. 6-OHDA; and the combined treatment group received both DMI and 6-OHDA. DSP-4 was injected i.p. in a dose of 50 mg/kg in 0.9% saline. This dose has been described to be maximally effective."
Three days after the injections, training procedures began for the BP measurements. Systolic BP and heart rate (HR) were measured on conscious animals with a tail-cuff method, as previously described. 23 Before the actual measurements were performed, the animals were trained daily to get used to the restraining cage and the tail cuff. Actual measurements of BP were performed daily during the 1st week and thereafter at least three times a week to minimize any stress-induced influences on the data. In general, the development of hypertension was followed for at least 3 weeks, after which the rats were decapitated, and their brains were taken out for dissection and catecholamine assay. Postdecapitation reflexes were assessed as the time during which limb movements occurred after decapitation. Thus, the time between decapitation and the actual occurrence of reflexes was not included in the present data. Frontal cortex, hypothalamus, hippocampus, and medulla/pons were obtained according to the dissection method of Gispen et al. 24 The hearts were briefly rinsed in cold saline, and then all tissue parts were quickly weighed and frozen on dry ice.
Before catecholamine assay, the brain tissue was homogenized with a Heidolph homogenizer (Heidolph Elektro KG, Kelheim, FRG), and the heart tissue was cut with a Polytron homogenizer, both in a volume of 0.1 N HC1O 4 appropriate to meet with the standard curve of the assays. Norepinephrine, dopamine, and in some experiments epinephrine were assayed in 20 /xl samples of the homogenates with a radioenzymatic assay according to the method of Van der Gugten et al. 25 Control and treatment groups of one experiment were always measured within one assay. In this way, interassay variations could not influence eventual treatment effects. Catecholamine concentrations are expressed as ng/100 mg tissue wet weight. Data are expressed as means ± standard error of the mean (SEM). For statistical comparison, Student's t test was used, in appropriate cases preceded by a one-way analysis of variance (ANOVA). A p value less than 0.05 (two-tailed) was considered to indicate a statistically significant difference.
Results
In 5-week-old WKY, SHR, and SHRSP, the effects of three i.c.v. injections of 50 or 200 /xg 6-OHDA on the BP are shown in Figure 1 . The development of hypertension was markedly attenuated by 3 x 200 /xg 6-OHDA, as shown by the significantly lower systolic BP when compared to vehicle-treated control rats (after 2 weeks, 171 ±3 mm Hg for 6-OHDA-treated SHR vs 182 ± 4 mm Hg for vehicle-treated SHR; and after 4 weeks, 160 ± 4 mm Hg vs 201 ±4 mm Hg, respectively). Injection of 3 x 50/xg 6-OHDA resulted in significantly lower systolic BP, but only after 4 weeks (187 ± 3 vs 201 ± 4 mm Hg). Treatment with 3 x 200 /xg 6-OHDA in WKY also resulted in lower systolic BP, but the difference was less than that found in SHR (after 2 weeks, 128 ± 2 mm Hg in 6-OHDAtreated WKY vs 138 ± 2 mm Hg in vehicle-treated WKY; after 4 weeks, 124 ± 2 vs 147 ± 4 mm Hg, respectively). Injection of 3 X 50/xg 6-OHDA did not significantly affect BP in WKY. In SHRSP, only the 3 X 200 /xg dose was studied. Significantly lower systolic BP was found at both time points (after 2 weeks, 178 ± 3 mm Hg in 6-OHDA-treated SHRSP vs 192 ± 6 mm Hg in vehicle-treated rats; after 4 weeks, 178 ± 4 vs 210 ± 4 mm Hg, respectively). Thus, treatment with 6-OHDA appeared to have marked effects on the development of hypertension in SHR and SHRSP, with only a small effect on the BP of WKY.
The HR was also affected by 6-OHDA treatment. As shown in Figure 1 , the 3 X 200 /xg dose resulted in significantly lower HR values in WKY, SHR, and SHRSP, although the extent of the difference was greater in both hypertensive strains. Only in WKY was the HR reduced after three 50 /xg injections.
Concentrations of norepinephrine in the frontal cortex, hypothalamus, and hippocampus of 6-OHDAtreated rats were markedly and significantly lower as compared to vehicle-treated control rats (Table 1) . This effect was dose-dependent. As little as 3 x 50 /xg 6-OHDA resulted in more than a 50% depletion of norepinephrine in all brain regions studied. In general, depletion of dopamine was less pronounced than that of norepinephrine.
Final body weight was slightly, although significantly, lower in rats of all three substrains after treatment with 3 x 200 /xg 6-OHDA (Table 1) . This effect can be attributed to a transient decrease in body weight caused by the first injection. Thereafter, body weight gain was similar in all groups. The lower dose of 6-OHDA did not affect body weight. 
FIGURE I. Effect of 3 X 50 fig (stippled bars) and 3 X 200 ng (black bars) of6-hxdro.\xdopamine (6-OHDA) on the systolic blood pressure (left panels) and heart rate (right panels) in Wistar-Kxoto (WKY), spontaneously hypertensive rats (SHR), and rats of the stroke-prone SHR-substrain (SHRSP), at 2 weeks (top panels) and at 4 weeks (bottom panels) after the first 6-OHDA injection For the number of animals, see Table I. * refers to a statistically significant dijjerence (p < 0.05, Student t test after AN OVA) as compared to control xxilues from vehicle-treated rats (open bars).
The effect of combined treatment with 6-OHDA and DMI on the time course of the development of hypertension in SHR is shown in Figure 2 . Data are only available for after Day 17 after the first injection, because of the recovery time and training procedure time. The effect of combined treatment did not differ from that of 6-OHDA treatment alone. In both groups, systolic BP was significantly lower than that found in the respective control groups, while a significant difference between 6-OHDA-treated SHR and combinedtreated SHR was found only on Days 25 and 42. OHDA, 3 X 200 fig i.c.v.) with and without pretreatment with After 6-OHDA treatment, SHR had markedly lower HR as compared to control rats treated with vehicle alone (Figure 2 ). This effect was not found in the SHR of the combined treatment group. At all time points, a significantly lower HR was found in 6-OHDA-treated SHR when compared to SHR treated with 6-OHDA and DMI.
The effect of 6-OHDA treatment on body weight did not differ with or without pretreatment with DMI (Table 2). Thus, in both treatment groups, an initial decrease in body weight occurred after the first injection of 6-OHDA, while body weight gain thereafter paralleled that of both control groups. Postdecapitation reflex time of 6-OHDA-treated SHR was shorter than that of vehicle-treated controls (Table 2) . However, the duration of the post-decapitation reflexes was significantly longer in SHR treated with 6-OHDA and DMI when compared to 6-OHDA-treated SHR.
Norepinephrine concentrations in the frontal cortex, hypothalamus, hippocampus, and medulla pons were markedly lower in 6-OHDA-treated SHR as compared to control rats (Table 2) . Dopamine concentrations were lower in the frontal cortex and hypothalamus. DMI pretreatment largely prevented the 6-OHDA-induced depletion of norepinephrine. The effect on dopamine level in the frontal cortex was not influenced, but in the hypothalamus no significant depletion was found after the combined treatment. Neither treatment had significant effects on epinephrine concentrations in the hypothalamus or medulla pons, although tendencies were sometimes observed.
The development of hypertension in SHR treated with DSP-4 was similar to that in vehicle-treated control rats. At none of the time points was a significant difference found between the systolic BP of SHR treated with DSP-4 or vehicle (at 5 weeks after injection, the BP in DSP-4-treated SHR was 205 ± 4 mm Hg and BRAIN CATECHOLAMINES AND SPONTANEOUS HYPERTENSIONAmi den Buuse et al. Values are means + SEM. *p < 0.05, between either 6-OHDA-treated rats and controls or between DMI + 6-OHDA-treated rats and DMl-treated rats. \p < 0.05, between DMI + 6-OHDA-treated rats and 6-OHDA-treated rats + Markedly decreased epinephrine concentrations were found in the hypothalamus of 6-OHDA-treated rats. However, analysis of variance indicated no statistically significant difference. On the basis of Student's (test, the difference between 6-OHDA-treated rats and controls would have been significant. in vehicle-treated SHR was 208 ± 3 mm Hg). Heart rate was slightly, though significantly, lower in SHR treated with DSP-4 (430 ± 7 bpm) as compared to control (468 ± 8 bpm) at 5 weeks after injection only. Final body weights were lower after treatment with DSP-4 (5 weeks after injection, 227 ± 3 g in treated SHR vs 242 ± 5 g in control). Postdecapitation reflex time in SHR treated with DSP-4 was significantly shorter than that found in vehicle-treated control rats (Table 3) . Except in the heart, norepinephrine concentration was significantly lower in all regions studied. Dopamine and epinephrine concentrations were not affected except for dopamine in the medulla pons (Table 3) .
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Discussion
The present experiments were performed to further analyze the role of central catecholamines in the development of hypertension in the SHR. From the results, a role for dopamine in this process is suggested. Treatment with 6-OHDA dose-dependently affected both BP and HR in SHR as well as in WKY and SHRSP. The treatment resulted in a dose-dependent depletion of norepinephrine and, to a lesser extent, of dopamine. Pretreatment with DMI in SHR did not substantially influence 6-OHDA-induced attenuation of the development of hypertension, but a marked protection of norepinephrine against the action of 6-OHDA was found. Dopamine depletion, however, was not influenced. Depletion of norepinephrine alone by DSP-4 did not significantly affect the BP.
The attenuating effect of high doses of i.c.v. 6-OHDA on the development of hypertension in SHR has been reported previously. 14~17 In the present experiments, WKY also displayed lower BP after 6-OHDA treatment, although less marked. A difference in the magnitude of the effect of several stimuli on the BP in SHR vs WKY has been described.
2 -3 In SHRSP, 6-OHDA resulted in markedly lower BP values, which suggests that catecholamines influence the development of hypertension in this substrain, as well.
Administration of lower doses of 6-OHDA to SHR has not been reported earlier. Although in some areas of the brain a more than 70% depletion of norepinephrine was found, only a small effect on the rise in BP occurred (at 4 weeks, -7% difference vs -20% after 3 X 200 /xg of 6-OHDA). This could suggest that only extensive depletion (80%-90%, or more) of norepinephrine may result in a substantial effect on the development of hypertension in SHR. An alternative explanation could be that only the high dose of 6-OHDA affects other, less sensitive, neurotransmitter systems in the brain. Thus, it was only after 3 x 200 /xg 6-OHDA that dopamine concentrations in the frontal cortex were depleted. A greater sensitivity of norepinephrine neurons to the action of 6-OHDA, as compared to dopamine neurons, has been described. tThe number of rats in the epinephrine determinations was 9 and 7, respectively. merit in the first experiment. The effect of 6-OHDA on HR, however, does seem to be dependent on depletion of norepinephrine, since DMI pretreatment almost completely returned the HR values to the level found in controls.
Treatment with DSP-4 did not significantly affect the development of hypertension and slightly decreased the HR in SHR. The DSP-4 has been introduced as a specific neurotoxin for norepinephrine neurons in the brain after peripheral administration. 19 -20 Although DSP-4 was injected i.p., no depletion of norepinephrine was found in the heart, which suggests that there was no interference of peripheral factors with the action of DSP-4. Norepinephrine levels in the brain were decreased, while there was little effect on dopamine and epinephrine. Postdecapitation reflex time was decreased in rats after treatment with DSP-4, which suggests that the spinal cord norepinephrine was also depleted. 27 Although the depleting effects of DSP-4 do not seem as marked as after treatment with 3 x 200 fig 6-OHDA, the absence of an effect of the treatment on the development of hypertension, together with an almost complete absence of dopamine depletion, could be interpreted as additional support for the results of the experiments with DMI. Higher doses of DSP-4 do not result in higher depletion values of norepinephrine in the brain."
In conclusion, the present results do not support a major role for norepinephrine in the development of hypertension in the SHR, but rather suggest an involvement of other systems, notably dopamine.
Recently, lesion studies have revealed that ascending noradrenergic pathways are not of major importance in the rise of BP in SHR. 13 17 Thus, forebrain depletion of norepinephrine by knife-cut lesions or by 6-OHDA-microinjections in the ascending noradrenergic bundles does not interfere with the development of spontaneous hypertension. The present results, for which DMI was used to specifically block the action of 6-OHDA against noradrenergic neurons, 18 support and extend these findings. The effect of DMI can probably be attributed to a blockade of the uptake of 6-OHDA into the neuron. 1213 A protecting action of DMI on norepinephrine neurons also in the spinal cord is suggested by the differences in the postdecapitation reflex time between the various treatment groups (Table 2) . 27 Recently, it has been shown that 6-OHDA-induced depletion of epinephrine can also be prevented by DMI.
2 * While the effects of 6-OHDA on the BP rise were not influenced by DMI pretreatment, it is noteworthy that dopamine depletion was not altered either. It is unlikely that the small remaining depletion of norepinephrine in the frontal cortex and hippocampus after combined treatment can account for the observed effects on BP, if we consider the even larger depletions of norepinephrine in these structures together with smaller effects on BP after 3 x 50 fig 6-OHDA treat-
